东方生物2025年度归母净亏损5.64亿元

Core Viewpoint - Dongfang Biological (688298.SH) reported a total operating revenue of 959 million yuan for the year 2025, representing a year-on-year increase of 15.83%. However, the net profit attributable to the parent company's owners was a loss of 564 million yuan, which has widened compared to the previous year [1] Group 1 - The company's main business has maintained steady development during the year [1] - Significant investments in the strategic development of various industrial technology platforms have contributed to the overall loss [1] - Factors such as exchange losses, reduced contributions from interest income, and increased depreciation and amortization expenses have negatively impacted net profit [1]